Alkermes plc (ALKS) Business Profile

What it does

Alkermes is a biopharmaceutical company focused on neuroscience. It develops and sells medicines for alcohol and opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. The company is headquartered in Ireland, with a corporate office and research center in Massachusetts and a manufacturing facility in Ohio. Blair Jackson is its chief executive.

Its U.S. products include VIVITROL, a monthly injection for alcohol dependence and prevention of relapse to opioid dependence after detoxification. ARISTADA is an extended-release injection for schizophrenia; ARISTADA INITIO helps patients start or restart ARISTADA treatment. LYBALVI is a daily oral medicine for adults with schizophrenia or bipolar I disorder.

LUMRYZ is a once-at-bedtime medicine for cataplexy or excessive daytime sleepiness in people with narcolepsy. Alkermes acquired the product and a narcolepsy commercial organization when it completed its acquisition of Avadel in February 2026. LUMRYZ is distributed under a safety program that requires certification of prescribers and pharmacies and enrollment of patients.

Alkermes also licenses medicines and drug-delivery technology to other companies. Janssen commercializes long-acting INVEGA products and RISPERDAL CONSTA, while Biogen has the worldwide license to develop and commercialize VUMERITY for multiple sclerosis. Alkermes earns royalties or manufacturing revenue from these arrangements. Its research pipeline includes medicines being studied for sleep disorders and other neurological and psychiatric conditions.

How it makes money

Alkermes earns revenue from sales of its own medicines and from royalties and manufacturing services tied to products commercialized by licensees. Its proprietary products are sold primarily through wholesalers, specialty distributors and pharmacies. Sales are reported net of adjustments, including rebates.

VIVITROL generated $467.9 million in FY2025. ARISTADA and ARISTADA INITIO generated $370.0 million, and LYBALVI generated $346.7 million. These figures precede the acquisition of LUMRYZ in February 2026. The company receives product revenue as medicines are sold; royalty revenue depends on licensees’ sales, while manufacturing revenue is generally recognized when a product has been fully manufactured.

Under its agreement with Biogen, Alkermes receives a 15% royalty on worldwide VUMERITY net sales, subject to increases when Biogen or its designees manufacture or package the product. Janssen pays royalties on licensed products under agreements with terms that vary by product and country. Alkermes also manufactures RISPERDAL CONSTA microspheres for Janssen and receives a manufacturing fee tied to Janssen’s net unit sales price and volume.

In January 2025, Alkermes raised prices by 3% for each of LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL. LYBALVI units sold increased 19% in 2025, while VIVITROL units fell 3% and ARISTADA/ARISTADA INITIO units fell 2%.

Total revenue for Q3 2026 was $480.1 million, including $417.3 million in proprietary product net sales and $62.9 million in manufacturing and royalty revenue. The company expects its proprietary portfolio to deliver net sales of nearly $1.6 billion in 2026.

Customers and how it sells

Alkermes sells its proprietary medicines primarily to wholesalers, specialty distributors and pharmacies. Healthcare providers prescribe the medicines for patients with the conditions for which they are approved. For LUMRYZ, prescribers and pharmacies must be specially certified, and patients must enroll in the required safety program before the drug can be dispensed.

Customer revenue is concentrated among distributors. McKesson accounted for 31.0% of revenue in FY2025, Cencora for 20.0%, and Cardinal Health for 17.0%. Alkermes also receives revenue through commercial relationships with licensees, including Janssen and Biogen, which sell products incorporating Alkermes medicines or technology.

The U.S. accounted for $1.4 billion, or 93.0%, of FY2025 revenue. Alkermes exclusively commercializes ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and LUMRYZ in the U.S. Its licensees sell certain products worldwide: Janssen commercializes the long-acting INVEGA products and RISPERDAL CONSTA, and Biogen holds the worldwide license for VUMERITY.

For LUMRYZ, Alkermes reported approximately 4,100 patients on therapy at the end of Q3 2026. Coverage and reimbursement from government and other third-party payers can affect use of its medicines.

Suppliers and costs

Alkermes manufactures ARISTADA, ARISTADA INITIO, LYBALVI, VIVITROL and RISPERDAL CONSTA microspheres at its Wilmington, Ohio facility. It purchases active ingredients from third parties or receives them from licensees, and outsources packaging for its proprietary products to contractors. LUMRYZ’s active ingredient is purchased, and its drug product is made by contract manufacturers in and outside the U.S.

Some materials and related services are available from only one source or a limited number of qualified sources. Alkermes seeks to maintain inventory, establish alternatives or negotiate long-term supply arrangements, but cannot be certain of continued long-term supply. Its facilities and those of outside manufacturers are subject to regulatory inspection.

Research and development costs include clinical and preclinical contractors, laboratory services, drug materials and outside manufacturing development, as well as employee and facility expenses. In Q3 2026, research and development expense was $121.1 million, compared with $81.7 million in Q3 of the prior year. Selling, general and administrative expense was $208.5 million, compared with $171.8 million in Q3 of the prior year; Alkermes attributed the increase primarily to the addition of Avadel’s commercial infrastructure.

Competitive position

Alkermes competes with branded and generic medicines across its treatment areas. In schizophrenia, ARISTADA and Janssen’s licensed long-acting products compete with one another and with injectable medicines developed or marketed by companies including Otsuka, Teva, MedinCell and Amneal. LYBALVI also competes with oral antipsychotics, including products sold by AbbVie and Bristol-Myers Squibb, as well as generic medicines.

VIVITROL competes with generic medicines for alcohol dependence and with opioid-dependence treatments sold by Indivior and other companies. LUMRYZ competes with other oxybate formulations, generic versions of XYREM and daytime wake-promoting agents, including products from Axsome Therapeutics and Harmony Biosciences. Alkermes also expects competing orexin medicines to affect the oxybate market.

Alkermes uses extended-release technologies in several products and holds patents and regulatory exclusivities. LUMRYZ has orphan drug exclusivity for adult and pediatric narcolepsy through May 1, 2030 and October 16, 2031, respectively. Alkermes says VIVITROL manufacturing requires specialized sterile facilities and formulation expertise.

Our reading: Drug-delivery and manufacturing expertise provide a potential barrier to competition, but rival delivery systems and generic products limit its strength. Our reading: Patents and regulatory exclusivity provide time-limited protection, rather than permanent insulation from competition, and Alkermes faces challenges to intellectual property covering some products.

Growth opportunities

Alkermes is expanding its sleep-medicine business following the Avadel acquisition. LUMRYZ is approved for narcolepsy, and Alkermes reported positive Phase 3 results from its study in idiopathic hypersomnia, a condition associated with excessive sleepiness. The company says those data will form the basis of a supplemental application for that indication; any additional use would require approval.

The company’s investigational medicine alixorexton targets the orexin system, which helps regulate wakefulness. Alkermes completed Phase 2 studies in narcolepsy types 1 and 2 and received breakthrough therapy designation for the type 1 indication. Its Phase 3 narcolepsy studies are underway, and Alkermes expects initial top-line results beginning in mid-2027. Enrollment has also been completed in the Phase 2 Vibrance-3 study in idiopathic hypersomnia, including an evaluation of split dosing.

Alkermes is studying another orexin candidate, ALKS 7290, in adults with ADHD. Its Phase 2 study is enrolling and compares dosing regimens with placebo. The company has also initiated a Phase 2 study of ALKS 7290 alongside antidepressants in adults with major depressive disorder who have had a partial response to standard treatment. It plans to study ALKS 4510 for fatigue associated with multiple sclerosis or Parkinson’s disease.

For its existing portfolio, LYBALVI revenue grew to $346.7 million in FY2025 from $280.0 million in FY2024. Alkermes has expanded access through contracting arrangements with Medicare Part D plans.

Structural risks

• Product and generic competition: Alkermes depends on successful manufacturing and commercialization of its key proprietary medicines. It has expected generic VIVITROL entry in 2027; the company has also said the timing of generic entry is uncertain. Greater competition may reduce unit sales and increase pricing pressure.
• Intellectual property and royalties: Patent protection is uncertain, and Alkermes is involved in litigation concerning LYBALVI patents. Royalties on U.S. INVEGA SUSTENNA sales expired in August 2024, and the company expects lower overall long-acting INVEGA royalties than when those payments were included.
• Development and approval: Clinical trials can be delayed or fail because of enrollment, safety, manufacturing or regulatory issues. The approval process can be costly and may not result in approval, even after earlier studies have succeeded.
• Supply and manufacturing: Some materials or services have only one or a limited number of qualified sources. Interruptions involving ingredients, manufacturing, packaging or regulatory inspections could impair product supply or development.
• Access and regulation: Reimbursement policies can affect use of Alkermes products. LUMRYZ is subject to a safety program requiring certified prescribers and pharmacies and enrolled patients; the associated requirements and perceptions of their burden may affect its use.

Bottom line

Our reading

Alkermes combines sales of proprietary neuroscience medicines with royalties and manufacturing revenue from licensed products. Our reading: Its commercial medicines and drug-delivery capabilities support investment in a broader pipeline, but product sales, third-party relationships and U.S. distribution remain important dependencies. The sleep portfolio adds a commercial product and development opportunities, while generic competition, expiring royalty streams and clinical and regulatory outcomes remain material uncertainties.